Cerapedics and Vizient signed a supplier agreement for the PearlMatrix P-15 peptide enhanced bone graft, according to an April 24 news release.
PearlMatrix is FDA approved for open or minimally invasive single-level anterior lumbar interbody fusion, posterior lumbar interbody fusion, oblique lumbar interbody fusion, lateral lumbar interbody fusion and transforaminal lumbar interbody fusion with PEEK titanoum cages.
The supplier agreement expands access to the bone graft for Vizient clients, which serves more than 65% of the nation’s acute care providers.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.